Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2009
10/22/2009WO2009105355A3 A novel neospora caninum vaccine
10/22/2009WO2009101475A3 Use of glycosylceramides for enhancing the immune response to antigens
10/22/2009WO2009097095A9 Methods for treating hematopoietic malignancies
10/22/2009WO2009097017A3 Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
10/22/2009WO2009095226A3 NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
10/22/2009WO2009093251A3 Reovirus vaccine based on sigma c protein sequence
10/22/2009WO2009092011A8 Cysteine engineered antibodies for site-specific conjugation
10/22/2009WO2009073905A3 Method for increasing immunoreactivity
10/22/2009WO2009041832A9 Vaccines and vaccine components for inhibition of microbial cells
10/22/2009WO2008100816A9 Antibody libray display by yeast cell plasma membrane
10/22/2009WO2007025085A8 Genemap of the human genes associated with crohn's disease
10/22/2009US20090265797 Novel Anti-IGF-IR Antibodies and Uses Thereof
10/22/2009US20090264627 Increasing half-life of immunoglobulin fusion via alteration of carboxy-terminal with cytokine protein; directed protein evolution; antitumor agents
10/22/2009US20090264624 Human cytokine receptor
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264381 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/22/2009US20090264364 Genes implicated in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
10/22/2009US20090263916 Antagonists of HMG1 for treating inflammatory conditions
10/22/2009US20090263883 Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus
10/22/2009US20090263865 Substance Specific to Human PD-1
10/22/2009US20090263864 Recombinant production of mixtures of antibodies
10/22/2009US20090263847 Lsr receptor, its activity, its cloning and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
10/22/2009US20090263788 Efficient algorithm for pcr testing of blood samples
10/22/2009US20090263783 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
10/22/2009US20090263474 Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
10/22/2009US20090263470 Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant
10/22/2009US20090263428 Artificial lymph node for treating cancer
10/22/2009US20090263427 Vaccines for mycoplasma bovis and methods of use
10/22/2009US20090263426 Methods for treating headache
10/22/2009US20090263425 Methods of stimulating an immune response against prostate specific antigen
10/22/2009US20090263424 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
10/22/2009US20090263423 Enhancement of an Immune Response by Administration of a Cationic Lipid-DNA Complex (CLDC)
10/22/2009US20090263422 Influenza vaccine
10/22/2009US20090263421 Cellular vaccine
10/22/2009US20090263420 Virus-Like Particles As Vaccines For Paramyxovirus
10/22/2009US20090263419 Live attenuated bacterial vaccine
10/22/2009US20090263418 Means and methods for manipulating sequential phagolysomalcytosolic translocation of mycobacteria, and uses thereof
10/22/2009US20090263417 Multi-subtype FIV vaccines
10/22/2009US20090263414 Bifunctional Protein Anchors
10/22/2009US20090263413 Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
10/22/2009US20090263412 Non-Splicing Variants of gp350/220
10/22/2009US20090263411 Compositions, splice variants and methods relating to ovarian specific genes and proteins
10/22/2009US20090263410 Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent
10/22/2009US20090263409 Cancer antigen peptide formulations
10/22/2009US20090263408 Formulation and presentation of medicaments
10/22/2009US20090263407 Cationic Lipids and Uses Thereof
10/22/2009US20090263406 JY-1 Regulation Of Granulosa Cell Function And Early Embryonic Development In Cattle
10/22/2009US20090263405 CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS
10/22/2009US20090263404 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
10/22/2009US20090263403 DNAX Accessory Protein, 12 kD (DAP12); useful in modulating development of cells such as lymphoid and myeloid; for modulating of immune responses; fusion proteins
10/22/2009US20090263402 Growth Differentiation Factor-11
10/22/2009US20090263401 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE
10/22/2009US20090263400 Osteoporosis associated markers and methods of use thereof
10/22/2009US20090263399 Method for establishing the sensitivity of tumours to capecitabin and test kit
10/22/2009US20090263398 Pharmaceutical combinations
10/22/2009US20090263397 Combination anti-cancer therapy
10/22/2009US20090263396 Inhibitors of t-darpp for use in combination anti-cancer therapies
10/22/2009US20090263395 Genes and polypeptides relating to breast cancers
10/22/2009US20090263394 A34 and a33-like 3 dna protein, antibodies thereto and methods of treatment using same
10/22/2009US20090263393 Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer
10/22/2009US20090263392 Methods of modifying antibodies for purification of bispecific antibodies
10/22/2009US20090263391 Antibodies that bind to epha2 and methods of use thereof
10/22/2009US20090263390 Method of treating cancer by co-administration of anticancer agents
10/22/2009US20090263389 Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection
10/22/2009US20090263388 Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists
10/22/2009US20090263387 Neutralization of GM-CSF for the Treatment of Heart Failure
10/22/2009US20090263386 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
10/22/2009US20090263385 Breast carcinoma treatment method
10/22/2009US20090263384 Agents for Suppressing the Induction of Cytotoxic T Cells
10/22/2009US20090263383 Antibodies to angiogenesis inhibiting domains of CD148
10/22/2009US20090263382 Stable and soluble antibodies inhibiting tnf alpha
10/22/2009US20090263381 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
10/22/2009US20090263380 Anti-idiotypic antibodies neutralizing the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii
10/22/2009US20090263379 Monoclonal antibodies for inhibition of laminin-8 expression to inhibit human gliomas
10/22/2009US20090263378 Methods of identifying anti-inflammatory compounds
10/22/2009US20090263377 Il-32b-targeted diagnosis and therapy
10/22/2009US20090263376 Breaking immunological toterance with a genetically encoded unnatural amino acid
10/22/2009US20090263375 Novel poly(a) polymerase
10/22/2009US20090263358 autologously transplanting hematopoietic progenitor cell population which has been treated with antibody (monoclonal, chimeric, or humanized; not conjugated to toxin or cytolytic agent); radiotherapy
10/22/2009US20090263353 Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles
10/22/2009US20090263352 Methods for treating viral infection using il-28 and il-29 cysteine mutants
10/22/2009US20090263351 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
10/22/2009US20090263349 Methods and compositions for inhibiting angiogenesis
10/22/2009US20090263348 Nucleic Acids Encoding Multimeric Fusion Proteins of TNF Superfamily Ligands
10/22/2009US20090263323 Novel means and methods for the treatment of hearing loss and phantom hearing
10/22/2009US20090263318 Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
10/22/2009DE102005027956B4 Hochattenuierte Poxvirusstämme, Verfahren zu ihrer Herstellung und deren Verwendung als Paramunitätsinducer oder zur Herstellung von Vektor-Vakzinen Poxvirusstämme highly attenuated, processes for their preparation and their use as paramunity inducers or for the preparation of vector vaccines
10/22/2009CA2759118A1 Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
10/22/2009CA2721568A1 An antibody bound synthetic vesicle containing active agent molecules
10/22/2009CA2721513A1 Chimeric porcine circovirus pcv2gen-1rep and uses thereof
10/22/2009CA2721246A1 Deletion mutants of flagellin and methods of use
10/22/2009CA2721169A1 Prostate specific membrane antigen antibodies and antigen binding fragments
10/22/2009CA2721156A1 Stable amyloid beta monomers and oligomers
10/22/2009CA2721032A1 Anti-areg/hb-egf antibodies and treatment
10/22/2009CA2720961A1 Vaccine
10/22/2009CA2720877A1 Vaccine
10/22/2009CA2720210A1 Compositions comprising antibodies or antibody fragments
10/22/2009CA2718787A1 Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus
10/21/2009EP2110669A1 Methods for the identification of allo-antigens and their use for cancer therapy and transplantation
10/21/2009EP2110434A1 Type-1 cytokine receptor GLM-R
1 ... 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 ... 1823